ABK-CDK4 / Abbisko - LARVOL DELTA

Discovery of ABK-CDK4, a selective and brain-penetrant CDK4 inhibitor (AACR 2026) - "Although the first generation dual CDK4/6 inhibitors— such as palbociclib, ribociclib, and abemaciclib—have demonstrated clinical efficacy in advanced breast cancer, inhibition of CDK6 would cause dose-limiting hematological toxicity. ABK-CDK4, developed by Abbisko Therapeutics, is a highly selective and brain-penetrant CDK4 inhibitor with the potential to address limitations of current CDK4/6 inhibitors. Its promising efficacy, selectivity, and other properties support further preclinical advancement toward clinical development."

Breast Cancer • Eye Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Retinoblastoma • Solid Tumor

Abbisko Therapeutics…announced that six preclinical study updates from its proprietary pipeline have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting (Abbisko Therap Press Release)

Preclinical • Solid Tumor